BRD7-IN-1

• UNSPSC Description:

  BRD7-IN-1, a modified derivative of BI7273 (BRD7/9 inhibitor), binds to a VHL ligand via a linker to form a PROTAC VZ185 (VZ185 against BRD7/9 with DC50s of 4.5 and 1.8 nM, respectively)[1].

• Target Antigen:

  Epigenetic Reader Domain

• Type:

  Reference compound

• Related Pathways:

  Epigenetics

• Applications:

  Neuroscience-Neuromodulation

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/brd7-in-1.html

• Purity:

  99.77

• Solubility:

  DMSO : 30 mg/mL (ultrasonic)|H2O : 100 mg/mL (ultrasonic)

• Smiles:

  CN1C=C(C2=CC(OC)=C(CN3CCNCC3)C(OC)=C2)C(C=CN=C4)=C4C1=O.Cl.Cl

• Molecular Weight:

  467.39

• References & Citations:

  [1]Zoppi V, et al. Iterative Design and Optimization of Initially Inactive Proteolysis Targeting Chimeras (PROTACs) Identify VZ185 as a Potent, Fast, and Selective von Hippel-Lindau (VHL) Based Dual Degrader Probe of BRD9 and BRD7. J Med Chem. 2019 Jan 24;62(2):699-726.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  4°C (Powder, sealed storage, away from moisture)

• Clinical Information:

  No Development Reported

• CAS Number:

  2448414-48-8